ERBB2 and ovarian cancer: The results showed that the molecular probe [177Lu]Lu-HP16, containing 9 nucleic acid bases, has the highest tumor/kidney uptake ratio and is a promising molecular probe for targeted therapy of HER2-positive ovarian cancer (121–123).